Healius Ltd
HLS: XASX (AUS)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
A$7.10 | Bmqp | Rmynhyqj |
Healius Earnings: Pathology Margins Weak but Set to Recover
No-moat Healius’ first-half fiscal 2024 group revenue and EBIT fell 2% and 61% to AUD 849 million and AUD 16 million, respectively. This was largely due to higher-margin coronavirus revenue falling 97% but was broadly in line with our expectations. As flagged, first-half group EBIT excluding coronavirus testing was flat on last year, weighed down by rent and wage inflation.